You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality
Eli Lilly and Company (LLY - Free Report) announced that the FDA has approved its calcitonin gene-related peptide (CGRP) antibody, Emgality (galcanezumab), for the preventive treatment of migraine in adults. The drug is approved as a once-monthly, self-administered, subcutaneous 120 mg injection. The company confirmed about the injection’s imminent launch.
The drug’s label mentions that patients suffering serious hypersensitivity should not be using the drug.
This is the third CGRP antibody to get an FDA nod for migraine treatment this year. While Teva’s (TEVA - Free Report) fremanezumab was approved earlier in September under the trade name of Ajovy, Amgen’s (AMGN - Free Report) and Novartis’ (NVS - Free Report) CGRP antibody, Aimovig/erenumab, was approved and launched in the United States during the second quarter of 2018. Considering that migraine has limited treatment options, the anti-CGRP comes as a new treatment mechanism.
Eli Lilly has set the price for Emgality as $575 for once-monthly or $6,900 annually in the United States. The annual price of Ajovy and Aimovig are on par with Emgality.
Shares of Eli Lilly have rallied 26.4% year to date, comparing favorably with the industry’s increase of 6.8%.
The FDA approval was based on data from two phase III clinical studies — The EVOLVE-1 and EVOLVE-2 as well as REGAIN. The first couple of analyses, spanning six months each, evaluated Emgality for the prevention of episodic migraine. While the third phase III REGAIN study with duration of three months was conducted on patients with chronic migraine. Data from all three programs showed that treatment with Emgality (120 mg) significantly lowered the mean monthly migraine headache days as compared to placebo.
Notably, Lilly's patient support program will help patients with commercial insurance (excluding governmental beneficiaries) to receive Emgality for free of cost up to 12 months.
Earlier this week, the Committee for Medicinal Products for Human Use (CHMP) conveyed a positive response, recommending approval for Emgality in Europe with a decision expected anytime soon.
Eli Lilly and Company Price and Consensus
Eli Lilly and Company Price and Consensus | Eli Lilly and Company Quote
Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>